文献类型：期刊文献

英文题名：Metal-linked Immunosorbent Assay (MeLISA): the Enzyme-Free Alternative to ELISA for Biomarker Detection in Serum

作者：Yu, Ru-Jia[1];Ma, Wei[1];Liu, Xiao-Yuan[1];Jin, Hong-Ying[1];Han, Huan-Xing[2];Wang, Hong-Yang[3];Tian, He[1];Long, Yi-Tao[1]

机构：[1]East China Univ Sci & Technol, Sch Chem & Mol Engn, Key Lab Adv Mat, Shanghai, Peoples R China;[2]Second Mil Med Univ, Changzheng Hosp, Translat Med Ctr, Beijing, Peoples R China;[3]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Lab Signal Transduct, Beijing, Peoples R China

年份：2016

卷号：6

期号：10

起止页码：1732

外文期刊名：THERANOSTICS

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001129766600002)】；

基金：This research was supported by the 973 Program (Grants 2013CB733700 and 2014CB748500), Fundamental Research Funds for the Central Universities (Grant 222201313004) and National Nature Science Foundation of China (Grant 21305045).

语种：英文

外文关键词：MeLISA

摘要：Determination of disease biomarkers in clinical samples is of crucial significance for disease monitoring and public health. The dominating format is enzyme-linked immunosorbent assay (ELISA), which subtly exploits both the antigen-antibody reaction and biocatalytic property of enzymes. Although enzymes play an important role in this platform, they generally suffer from inferior stability and less tolerant of temperature, pH condition compared with general chemical product. Here, we demonstrate a metal-linked immunosorbent assay (MeLISA) based on a robust signal amplification mechanism that faithfully replaces the essential element of the enzyme. As an enzyme-free alternative to ELISA, this methodology works by the detection of alpha-fetoprotein (AFP), prostatic specific antigen (PSA) and C-reactive protein (CRP) at concentrations of 0.1 ng mL(-1), 0.1 ng mL(-1) and 1 ng mL(-1) respectively. It exhibits approximately two magnitudes higher sensitivity and is 4 times faster for chromogenic reaction than ELISA. The detection of AFP and PSA was further confirmed by over a hundred serum samples from hepatocellular carcinoma (HCC) and prostate cancer patients respectively.